Advertisement

November 9, 2020

OrbusNeich Partners With P+F to Deliver Heart Valve Devices in Asia Pacific Region

November 9, 2020—OrbusNeich Medical Co. Ltd and P+F Products + Features GmbH announced they have entered into an agreement for the exclusive distribution and manufacturing of a range of minimally invasive heart valve products in the Asia Pacific region, including China, Japan, Taiwan, South Korea, Hong Kong, Singapore, Malaysia, Australia, and New Zealand.

According to the companies, P+F will bring to the partnership a series of minimally invasive heart valve products premounted on the delivery system using P+F’s dry valve technology. The product portfolio includes the TricValve transcatheter bicaval valves and the Vienna aortic self-expandable transcatheter valve, complemented by transcatheter solutions for pulmonary and mitral valve disease as well as endovascular grafts. Both the TricValve and Vienna are pending CE Mark approval.

The TricValve device is a system of two self-expanding biological valves for the treatment of patients with hemodynamically relevant tricuspid insufficiency and caval reflux, specifically intended for patients at extreme risk or who are unsuitable for open heart surgery.

The Vienna valve is designed to treat severe aortic stenosis in patients at medium to high risk for open heart surgery. The minimally invasive valve replaces the native aortic valve without the need for concomitant surgical removal.

David Chien, Chairman, President, and Chief Executive Officer of OrbusNeich, commented in the announcement, “We are delighted to collaborate with P+F and to establish a strong presence in a large and fast-growing transcatheter heart valve market in Asia Pacific. Both China and Japan face the challenge of a growing elderly patient population with the prevalence of moderate-to-severe dysfunctional heart valves. Our unique product line for percutaneous transcatheter-based therapeutics will result in significant improvement of health-related quality of life to our patients, which is an important measure of procedural success in the elderly.”

Also, in the press release, P+F Chief Executive Officer Katharina Kiss, MD, stated, “Partnering with OrbusNeich is an ideal opportunity for us to expand our vision by bringing our innovative heart valves technology to patients. My mission as a cardiologist is not only to save lives but to ensure the maximum quality of life for each of our patients, and I am convinced that with the joint efforts of this newly founded Asian joint venture, we will be able to revolutionize the medical landscape.”

Advertisement


November 12, 2020

RAPID Registry Evaluates Thromboaspiration With AngioDynamics’ AngioVac System

November 6, 2020

AstraZeneca’s Brilinta Is Approved to Reduce the Risk of Stroke